New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
12:46 EDTMRK, JNJ, UNH, HPQ, CAT, ZIP, CAR, SKUL, LNKDOn The Fly: Midday Wrap
Stocks on Wall Street were significantly higher at midday after U.S. lawmakers agreed on a deal to avoid some of the tax hikes associated with the fiscal cliff, but many of the issues remaining were simply pushed off by the last-second agreement. The stop-gap measure puts off the drastic spending cuts that were due to take effect, but it did not eliminate them, and it failed to raise the debt limit, meaning another political showdown is coming. The day’s economic data points went largely unnoticed as most investors breathed a sigh of relief and sent the averages soaring right at the opening bell... ECONOMIC EVENTS: In the U.S., Markit's final reading for December's purchasing managers' index came in at 54.0, which was up from 52.8 a month ago and beat expectations for a downward revision to 53.6. The ISM's December manufacturing PMI had a reading of 50.7, versus the expected 50.5, while the prices paid index came in at 55.5, versus the expected 50.8. A separate report showed construction spending fell 0.3% in November, versus an expected increase of 0.6%. In Europe, Markit's zone-wide PMI edged down to 46.1 in December, compared with its 46.3 preliminary reading and down from 46.2 in November... COMPANY NEWS: Every member of the Dow Jones Industrial Average was higher at midday, with only Merck (MRK), Johnson & Johnson (JNJ) and UnitedHealth (UNH) logging gains of less than 1%. Shares of Hewlett-Packard (HPQ) and Caterpillar (CAT) paced the blue chip index, as each rose over 4%... Reflecting a trend similar to the one seen on the Dow, every S&P sector except for Healthcare was significantly higher... MAJOR MOVERS: Among the notable gainers was Zipcar (ZIP), which rose 48% following its agreement to be acquired for $12.25 per share in cash by Avis Budget (CAR), which also had its shares rise nearly 5%. Among the noteworthy losers were Skullcandy (SKUL), down 14% after Jefferies downgraded the stock to Underperform from Buy, and LinkedIn (LNKD) which fell almost 4% after being downgraded to Equal Weight at Barclays... INDICES: Near 12:30 pm ET, the Dow was up 224.78, or 1.72%, to 13,328.92; the Nasdaq was up 67.24, or 2.23%, to 3,086.75; and the S&P 500 was up 24.81, or 1.74%, to 1,451.00.
News For MRK;JNJ;UNH;HPQ;CAT;ZIP;CAR;SKUL;LNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
October 14, 2014
07:49 EDTJNJJohnson & Johnson raises FY14 EPS to $5.92-$5.97 from $5.85-$5.92
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson reports Q3 domestic sales up 11.6% to $8.84B
Reports Q3 international sales down 0.3% to $9.63B. Worldwide, domestic and international operational sales growth, excluding the impact of this divestiture, was 8.4%; 14.8% and 3.1% respectively.
07:47 EDTHPQHP awarded $50M Medicaid contract extension by Massachusetts
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q3 adjusted EPS $1.50, consensus $1.44
Subscribe for More Information
07:05 EDTUNHUnitedHealth October volatility elevated into Q3 and guidance
Subscribe for More Information
October 13, 2014
16:04 EDTSKULSkullcandy announces two ASTRO headsets compatible with Xbox One
Subscribe for More Information
15:24 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
14:24 EDTJNJJohnson & Johnson October volatility increases into Q3 and outlook
Subscribe for More Information
14:15 EDTJNJEarnings Preview: Johnson & Johnson looks to new drugs to boost Q3 sales
Subscribe for More Information
14:08 EDTJNJJohnson & Johnson technical notes before earnings
Subscribe for More Information
11:46 EDTHPQHP nears six-month lows, levels to watch
Subscribe for More Information
10:26 EDTSKULSkullcandy management to meet with Roth Capital
Subscribe for More Information
09:23 EDTHPQHP could buy lower valuation company, says Bernstein
Subscribe for More Information
09:21 EDTHPQOn The Fly: Pre-market Movers
Subscribe for More Information
08:40 EDTJNJAlios BioPharma reports positive results for AL-8176 in Phase 2 study
Alios BioPharma presented results from a randomized, double-blind, placebo-controlled Phase 2 challenge study of its oral anti-RSV nucleoside analog AL-8176 this past weekend at the IDWeek 2014 Conference in Philadelphia, PA. The study was conducted in healthy adult volunteers who were infected intranasally with respiratory syncytial virus, or RSV. AL-8176 achieved its primary and secondary endpoints of reduction in viral load and improvement in symptom scores as compared to placebo. AL-8176 was well tolerated with no discontinuations of study drug and no clinically significant laboratory abnormalities. In successfully infected subjects, a rapid and marked reduction in RSV viral load was observed following treatment in all three AL-8176 treated dose groups as compared to placebo. In contrast, successfully infected placebo subjects exhibited a logarithmic increase in RSV RNA with a peak viral load at Day 3.5 following start of dosing with placebo. The mean time to non-detectability of RSV RNA was 1.3-2.3 days for the AL-8176 treatment groups compared to 7.2 days in the placebo group. At discharge, all subjects treated with AL-8176 were RSV RNA undetectable and remained RSV RNA undetectable upon follow-up on Days 16 and 28. The viral load reduction in infected subjects across all AL-8176 dosing regimens was associated with concomitant improvements in RSV symptom scores and reductions in mucus weight. On September 30, Johnson & Johnson announced a definitive agreement to acquire Alios.
08:05 EDTJNJBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:37 EDTMRKAmerican Society of Anesthesiologists to hold annual meeting
Subscribe for More Information
07:25 EDTJNJEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
07:15 EDTJNJ, UNHNational Association of Corporate Directors to hold a conference
Subscribe for More Information
07:13 EDTJNJBioFlorida to hold a conference
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use